Click here to buy Avelox online!

Avelox Information

Avelox is an antibiotic.

Avelox kills certain bacteria or stops their growth. Avelox is used to treat bronchitis, pneumonia, sinusitis, and certain skin infections.

Avelox Work Information

Avelox contains the active ingredient moxifloxacin hydrochloride, which is a type of medicine known as a quinolone antibiotic. Avelox is used to treat infections of the airways caused by bacteria.

Avelox works by entering bacterial cells and inhibiting the action of two bacterial enzymes, called topoisomerase II (DNA-gyrase) and IV. These enzymes are involved in the replication and repair of bacterial genetic material (DNA); processes that are needed for the bacteria to multiply.

The inhibition of these bacterial enzymes and hence the interference with the bacterial DNA, ultimately results in Avelox killing the bacteria.

Avelox kills a variety of different types of bacteria that cause infections such as bronchitis, pneumonia and sinusitis.

Click here to buy Avelox online!

Special information on Avelox

Most Important Fact about Avelox: Finish the full course prescribed by your prescriber or health care professional even if you think your condition is better. Do not stop taking Avelox except on your prescriber's advice. If you stop taking Avelox too soon, surviving bacteria could cause a relapse.

Avelox precautions if you are pregnant or breastfeeding: Avelox use is not recommended during pregnancy since fluoroquinolones have been reported to cause bone development problems in young animals.

Avelox may pass into breast milk. Breastfeeding mothers should not use Avelox . Seek medical advice from your doctor.

Special warnings about Avelox: Tell your doctor or pharmacist if you are taking any other medicines, including herbal medicines and those bought over the counter, before you start treatment with Avelox .

Avelox must not be taken in by people taking any of the following medicines, as this may increase the risk of abnormal heart rhythms (prolonged QT interval on the heart monitoring trace or ECG):

medicines to treat abnormal heart rhythms, e.g. amiodarone, procainamide, quinidine, disopyramide, sotalol tricyclic antidepressants, e.g. amitriptyline, imipramine certain antipsychotics, e.g. thioridazine, chlorpromazine, sertindole, haloperidol, pimozide the antihistamines astemizole, terfenadine or mizolastine certain antimicrobials, e.g. intravenous erythromycin or pentamidine antimalarials, e.g. halofantrine, chloroquine, quinine cisapride.

Avelox should be used with caution in people who are taking medicines that can reduce the amount of potassium in the blood, as if low blood potassium occurs there may be an increased risk of abnormal heart rhythms. Medicines that can lower blood potassium include the following:

corticosteroids, e.g. beclometasone, prednisolone diuretics, e.g. bendrofluazide, frusemide beta agonist bronchodilators, e.g. salbutamol.

An interval of about six hours should be left between taking Avelox and any of the following:

antacids containing magnesium or aluminium didanosine tablets sucralfate preparations containing iron or zinc.

The manufacturer of this medicine recommends that people who are taking anticoagulant medicines to prevent blood clots, e.g. warfarin, should have their blood clotting time (INR) monitored more frequently while taking Avelox.

Click here to buy Avelox online!

Why Avelox should not be prescribed ?

Avelox should not be used if you are allergic to one or any of its ingredients. Please inform your doctor or pharmacist if you have previously experienced such an allergy.

If you feel you have experienced an allergic reaction, stop using Avelox and inform your doctor or pharmacist immediately.

Has anyone used avelox with adverse reactions? Im getting stomach cramps, little sharp pains and all, and it feels like i have to burp but i dont. I just took my first pill lastnight, could that be doingit? Adam Quote:Originally Posted by adam2000 Has anyone used avelox with adverse reactions? Im getting stomach cramps, little sharp pains and all, and it feels like i have to burp but i dont. I just took my first pill lastnight, could that be doingit? Adam It's possible. Be sure to take it with plenty of food. OK - Make that Stomache Cramps and Dizziness....anything I can do to calm the stomach? The dizziness I dont think i have much of a choice with.... free daily porn free daily porn free daily porn Originally Posted by adam2000 OK - Make that Stomache Cramps and Dizziness....anything I can do to calm the stomach? The dizziness I dont think i have much of a choice with.... Adam Try some cola syrup. It might not work, but it's worth a try!

Schering-Plough Corporation (NYSE: SGP) today reported that monotherapy with the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) was as effective and well tolerated as a standard multi-dose combination antibiotic regimen in the treatment of patients with complicated intra-abdominal infections (cIAI), according to results of a study involving 681 patients published in the current issue of the Annals of Surgery.(1) AVELOX, the only marketed fluoroquinolone antibiotic approved by the U.S. Food and Drug Administration (FDA) as monotherapy to treat cIAI, was shown to be effective at eradicating the most common bacteria that cause cIAI, including E. coli and B. fragilis. In the study, patients who took 400 mg once daily of AVELOX intravenous (I.V.) followed by oral monotherapy achieved similar clinical cure rates (80 percent) at the test-of-cure visit (the primary efficacy endpoint) as patients who took a standard regimen of I.V. piperacillin-tazobactam followed by oral amoxicillin-clavulanate (78 percent). Importantly, AVELOX demonstrated a significantly higher cure rate of 82 percent - compared to 55 percent for the combination therapy - among patients who acquired their cIAI in a hospital setting (including both mild-to-moderate and more severe hospital-acquired infections). Hospital-acquired infections are often caused by more resistant bacteria than community-acquired infections. Clinical cure rates for patients with community-acquired infections were similar between the two treatment groups. The incidence of adverse events in the study due to any cause was similar for the two treatment groups, with the majority being mild or moderate in nature. The most common adverse events were nausea, hypokalemia, abdominal pain and constipation. The incidence of drug-related serious adverse events or premature discontinuation due to adverse events was similar for the two treatment groups. "The results of this study are important because complicated intra-abdominal infections are typically caused by mixed bacteria and require both surgery or drainage of the infection site and broad-spectrum antibiotic therapy for effective treatment," said Mark Malangoni, M.D., lead study investigator and Professor of Surgery at Case Western Reserve University School of Medicine and Surgeon-in-Chief at MetroHealth Medical Center in Cleveland. "AVELOX has demonstrated potent activity against the bacteria most common in these infections and is a safe and effective treatment. It also can be continued as a once-daily tablet, which is convenient for patients." AVELOX is indicated to treat polymicrobial cIAI infections, including infections caused by mixed aerobic and anaerobic bacteria (bacteria that thrive without oxygen) commonly seen in patients with cIAI.(2,3) "One fixed dose of AVELOX offers physicians a convenient treatment option with no dose adjustment required as symptoms improve and patients transition from intravenous (hospital-based) to oral therapy," said Joseph S. Solomkin, M.D., Professor in the Department of Surgery and Director of Research of the Division of Trauma/Critical Care at the University of Cincinnati College of Medicine, and a leading expert in the field. "The key benefit of staying with the same agent is the knowledge that the patient responded to it intravenously and can continue with the oral form when they leave the hospital." Complicated intra-abdominal infections are caused by disease, trauma or surgery in the abdomen that can allow bacteria to leak from the gastrointestinal tract into adjacent tissue. The biggest challenge to effective cIAI treatment is early recognition of the problem; the sooner the infection is diagnosed, the greater the chance that the physician will prescribe an effective treatment.(4) In the absence of effective cIAI therapy, treatment failure and mortality rates increase. Clinical practice guidelines recommend that antimicrobial therapy should begin as soon as infection is suspected, before an exact diagnosis is confirmed.(5) There are approximately 3.5 million annual cases of cIAI in the United States.(6) ---------------------------- Article adapted by Medical News Today from original press release. ---------------------------- About the Study In this prospective, randomized, double-blind, comparative, multicenter clinical trial, 681 patients from 71 sites in the United States, Canada and Israel were randomized to receive either sequential (I.V. followed by oral) AVELOX, 400 mg once daily regardless of route of administration, or I.V. piperacillin-tazobactam, 3.0/0.375 g four times a day, followed by oral amoxicillin-clavulanate, 800/114 mg twice daily. A total of 656 patients were included in the intent-to-treat analysis and of these 379 were found valid to assess efficacy (183 AVELOX/196 piperacillin-tazobactam). Patient baseline medical characteristics were similar for the two treatment groups. The duration of combined I.V./oral treatment in the study was 5-14 days. This study served as the basis for FDA approval of AVELOX for the treatment of cIAIs in November 2005. About Complicated Intra-Abdominal Infections (cIAI) Complicated intra-abdominal infections arise from the hollow organs of the peritoneal cavity, including the stomach, small and large bowel, appendix and biliary system. Types of cIAI include appendicitis with perforation or abscess, intra-abdominal abscess or peritonitis (diffuse inflammation of peritoneum lining the abdominal wall and bowel), perforations of the stomach or bowel, and surgical site infections related to previous intra-abdominal surgery. Generally, cIAI are acquired when the integrity of the gastrointestinal (GI) tract is affected as a result of previous surgery, intrinsic disease or trauma. The leakage of bacteria from within the GI tract into adjacent tissues results in infection. In the case of post-surgical infections, cIAI are caused by nosocomial bacteria specific to the surgical site and to the specific hospital and unit. About AVELOX AVELOX, available in tablet and I.V. formulations, was developed by Bayer Pharmaceuticals Corporation and is marketed in the United States by Schering-Plough. AVELOX offers patients a once-daily dosing regimen that does not require dosage adjustment when switching from I.V. to oral therapy. AVELOX patients suffering from renal impairment do not need to have their dosage adjusted. AVELOX is approved for use in adult patients (18 years of age and older) for the treatment of: Acute Bacterial Sinusitis (ABS) caused by Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis; Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus or Moraxella catarrhalis; Community Acquired Pneumonia (CAP) caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae or Chlamydia pneumoniae; Uncomplicated Skin and Skin Structure Infections (uSSSI) caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes; Complicated Skin and Skin Structure Infections (cSSSI) caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae or Enterobacter cloacae; and Complicated Intra-Abdominal Infections (cIAI) including polymicrobial infections such as abscesses caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron or Peptostreptococcus species. *MDRSP, Multi-drug resistant Streptococcus pneumoniae, includes isolates previously known as PRSP (Penicillin-resistant Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotic classes: penicillin (MIC greater than or equal to 2 mcg/mL), second generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. SAFETY INFORMATION about AVELOX AVELOX is generally well tolerated, with adverse events being similar to standard therapy. The most common side effects caused by AVELOX, which are usually mild, include dizziness, nausea and diarrhea. Patients should be careful about driving or operating machinery until they are sure that AVELOX is not causing dizziness. Patients should inform a health care professional of other side effects. Patients who have ever had an allergic reaction to AVELOX or any of the other group of antibiotics known as "quinolones" should avoid taking AVELOX. Patients who have been diagnosed with an abnormal heartbeat such as an arrhythmia or are using certain medications used to treat an abnormal heartbeat should avoid taking AVELOX. AVELOX is not for use during pregnancy or nursing, as the effects on the unborn child or nursing infant are unknown. AVELOX is not for children under the age of 18 years. Convulsions have been reported in patients receiving quinolone antibiotics. Patients should be sure to let their physician know if they have a history of convulsions. Many antacids and multivitamins may interfere with the absorption of AVELOX and may prevent it from working properly. Patients should take AVELOX either 4 hours before or 8 hours after taking these products. Please see full prescribing information for AVELOX available at http://www.aveloxusa.com/. About Schering-Plough Corporation Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 32,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com/. SCHERING-PLOUGH DISCLOSURE NOTICE: This press release contains certain "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including statements related to the potential market for AVELOX. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition and the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A. Risk Factors in the Company's 2005 10-K. References 1. Malangoni MA, et al. Randomized Controlled Trial of Moxifloxacin Compared with Piperacillin-Tazobactam and Amoxicillin-Clavulanate for the Treatment of Complicated Intra-Abdominal Infections. Annals of Surgery 2006;244:204-211. 2. Golan Y, McDermott LA, Jacobus NV, et al. Emergence of fluoroquinolone resistance among Bacteroides species. Journal of Antimicrobial Chemotherapy 2003;52:208-13. 3. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrobial Agents and Chemotherapy 2004;48:1012-6. 4. Solomkin JS, et al. Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections. Clinical Infectious Diseases, 2003;37:997-1005. 5. Ibid. 6. The Hospital Antibiotic Market Guide by AMR/Arlington Medical Resources, Inc.; MAT June 2004. (Intra-abdominal Infection cases based on Bayer HealthCare customized definition.) free daily porn free daily porn free daily porn

Generic Name: Moxifloxacin hydrochloride Product Name: Avelox Indication of Avelox: Used in adults for the treatment of infections caused by micro-organisms susceptible to Moxifloxacin. Including: Acute bacterial sinusitis; community-acquired pneumonia; acute exacerbations of chronic bronchitis. Intravenous use in adults is indicated for the treatment of moderate and severe infections caused by susceptible pathogens. Including: Community-acquired pneumonia; acute exacerbations of chronic bronchitis (where the responsible organisms display proven resistance to, or where there is intolerance to other antibiotics) Action of Avelox: Moxifloxacin in a synthetic, broad spectrum quinolone antibiotic with bactericidal action. The bactericidal activity results from an inhibition of bacterial DNA repair, transcription, repair and recombination, and is concentration dependent. Moxifloxacin shows in vitro and clinical activity against most strains of the following pathogens: S.pneumoniae, S.aureus, H.influenzae, H.parainfluenzae, K.pneumoniae, M.catarrhalis, C.pneumoniae, M.pneumoniae. Moxifloxacin is rapidly and almost completely absorbed from the gut following oral administration. Food does not effect the degree of absorption. Plasma concentrations are dose proportional. Mean elimination half life is 11-13 hours, with steady state achieved after about 3 days following a 400 mg once daily dose regimen. Moxifloxacin is mainly bound to serum albumin, and distributes widely through the body, including to saliva, nasal and bronchial secretions, and sinus mucosa. Elimination rates from tissues correlated with elimination from plasma. Moxifloxacin is metabolised in the liver (the cytochrome P450 system is not involved). Most of the metabolised drug is excreted in the faeces, some is excreted in the urine. Dose Advice of Avelox: Acute bacterial sinusitis: 400 mg orally, once daily, for 10 days. Acute bacterial exacerbation of chronic bronchitis: 400 mg orally, once daily, for 5 days OR 400 mg sequential intravenously/orally for 5 days. Community acquired pneumonia: 400 mg orally, once daily, for 10 days OR 400 mg sequential intravenously/orally for 7-14 days. Elderly, Patients with Renal or Hepatic Impairment: Dosage adjustment is not required in elderly patients, patients with renal impairment, or patients with mild/moderate hepatic impairment. The use of moxifloxacin in patients with severe hepatic impairment has not been sufficiently studied. Children: The use of moxifloxacin is not recommended in the paediatric population. Use in pregnant or lactating women: The use of moxifloxacin in pregnant or breastfeeding women is not recommended. Common side effects of Avelox: Abdominal pain, nausea, diarrhoea, vomiting, dyspepsia, abnormal liver function tests. Headache, dizziness. Injection site reaction. Uncommon side effects of Avelox: Pain, malaise, arthralgia, myalgia Insomnia, nervousness, anxiety, tremor, vertigo. Tachycardia, palpitations, hypertension, shortness of breath, oedema. Rash, pruritus, sweating. Moniliasis, vaginitis. Pseudomembranous colitis For further information talk to your doctor.

Answers: No, it's not used for smoking. It's an antibiotic (more precisely it's moxifloxacin, a broad spectrum fluoroquinolone antibiotic). All that translates into is that it kills a wide variety of bacterial infections such as bronchitis, sinus infections, skin infections, etc. Other Answers: to quit smoking Avelox, or moxifloxacin is an anti-infective. This means it is used to treat infection. Some of the common uses include treatment of: urinary tract and gynecologic infections, gonorrhea, respiratory tract infections, and skin infections. It can be used for other infections too. Basically it kills bacteria. free daily porn free daily porn free daily porn

Avelox Active Ingredients: Moxifloxacin Representative Names: Avelox What are moxifloxacin tablets? (Back to top) MOXIFLOXACIN (Avelox®, Avelox® ABC Pack™) is an antibiotic. It kills certain bacteria or stops their growth. It is used to treat bronchitis, pneumonia, sinusitis, and certain skin infections. Generic moxifloxacin tablets are not yet available. What should I tell my health care provider before I take this medicine? (Back to top) They need to know if you have any of these conditions: •diabetes •heart disease •liver disease •long exposure to sunlight (working outdoors) •seizures (convulsions) •stomach problems (especially colitis) •stroke •tendon or joint pain •other chronic conditions •an unusual or allergic reaction to fluoroquinolone antibiotics, foods, dyes, or preservatives •pregnant or trying to get pregnant •breast-feeding How should I take this medicine? (Back to top) Take moxifloxacin tablets by mouth with or without food. Follow the directions on the prescription label. Swallow tablets whole with a full glass of water. Take your doses at regular intervals. Do not take your medicine more often than directed. Finish the full course prescribed by your prescriber or health care professional even if you think your condition is better. Do not stop taking except on your prescriber's advice. Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed. What if I miss a dose? (Back to top) If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, take only that dose. Do not take double or extra doses. What drug(s) may interact with moxifloxacin? (Back to top) •aluminum salts •antacids •arsenic trioxide •astemizole •bepridil •certain heart medications for irregular rhythm (e.g., amiodarone, disopyramide, dofetilide, flecainide, ibutilide, quinidine, procainamide, sotalol) •certain medications for depression or other mental problems (e.g., tricyclic antidepressants, amoxapine, maprotiline, phenothiazines, haloperidol, pimozide, risperidone, sertindole, and ziprasidone) •cisapride •clarithromycin •cyclobenzaprine •cyclosporine •didanosine (ddI) •diuretics (water pills) such as furosemide or hydrochlorothiazide which can cause low potassium levels •dolasetron •doxercalciferol •droperidol •erythromycin •iron (ferrous sulfate) preparations •levomethadyl •magnesium salicylate •magnesium salts •manganese •medicines for diabetes •multivitamins that contain iron, magnesium, manganese, or zinc •NSAIDs such as Advil®, Aleve®, ibuprofen, Motrin®, naproxen •pentamidine •probucol •quinapril •retinoid products such as tretinoin (Retin-A®, Renova®) or isotretinoin (Accutan®) •sevelamer •sucralfate •terfenadine •troleandomycin •warfarin •zinc salts •ziprasidone Tell your prescriber or health care professional about all other medicines you are taking, including non-prescription medicines, nutritional supplements, or herbal products. Also tell your prescriber or health care professional if you are a frequent user of drinks with caffeine or alcohol, if you smoke, or if you use illegal drugs. These may affect the way your medicine works. Check with your health care professional before stopping or starting any of your medicines. What side effects may I notice from taking moxifloxacin? (Back to top) Side effects that you should report to your prescriber or health care professional as soon as possible: Rare or uncommon: •confusion •difficulty breathing •irregular heartbeat, palpitations or chest pain •joint, muscle or tendon pain •seizures •severe or watery diarrhea •skin rash, itching •swelling of the face or neck •tingling in hands or feet •tremor or restlessness •unusual tiredness or weakness •vision problems •vomiting Side effects that usually do not require medical attention (report to your prescriber or health care professional if they continue or are bothersome): •diarrhea •difficulty sleeping •dizziness •headache •nausea or stomach upset What should I watch for while taking moxifloxacin? (Back to top) Tell your prescriber or health care professional if your symptoms do not improve in 2 to 3 days. If you get an unusual reaction stop taking moxifloxacin and call your prescriber or health care professional for advice. If you are a diabetic, monitor your blood glucose carefully while on this medicine. You may get dizzy. Do not drive, use machinery, or do anything that needs mental alertness until you know how moxifloxacin affects you. To reduce the risk of dizzy or fainting spells, do not sit or stand up quickly, especially if you are an older patient. Many antacids and multivitamins can interfering with absorption of moxifloxacin. This may stop moxifloxacin from working. Take moxifloxacin either 4 hours before or 8 hours after taking any of these products. If you notice symptoms such as pain, burning, tingling, numbness and/or weakness, stop taking moxifloxacin and contact your healthcare provider immediately. If you notice pain or swelling of a tendon or around a joint, stop taking moxifloxacin. Rest the affected area and call your healthcare provider. Do not exercise or resume taking moxifloxacin until your healthcare provider tells you to do so. Keep out of the sun, or wear protective clothing outdoors and use a sunscreen. Do not use sun lamps or sun tanning beds or booths. If you are going to have surgery, tell your prescriber or health care professional that you are taking moxifloxacin. Where can I keep my medicine? (Back to top) Keep out of the reach of children in a container that small children cannot open. Store at room temperature in a tightly closed container. Avoid high humidity. Throw away any unused medicine after the expiration date.

AVELOX® (moxifloxacin hydrochloride) Tablets AVELOX® I.V. (moxifloxacin hydrochloride in sodium chloride injection) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX® and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

(Updating to add comment on outstanding Teva suit, details on Avelox) FRANKFURT (Thomson Financial) - Bayer AG said a US court ruled in favour of the German drugs and chemicals maker in a case in which Indian generic drug maker Dr Reddy's Laboratories challenged the validity of two US patents for antibiotic Avelox. Dr Reddy's had filed an Abbreviated New Drug Application (ANDA) for approval of a generic version of Avelox prior to the expiration of Bayer's patents, the German drugs and chemicals maker said in a statement. "Under US law, the filing of the ANDA is an act of patent infringement," Bayer said, adding it is nonetheless not unusual for generic drug companies to file ANDAs on successful pharmaceutical products prior to the expiration of the relevant patents. The ruling was made by the US District Court of the District of Delaware. Teva Pharmaceutical Industries also challenged the validity of the same Bayer patents in a case pending in the same court. Trial of Teva's case is scheduled to start on Feb 25, 2008. "Bayer intends to defend its patents vigorously," the company said. Avelox is approved in the US to treat acute exacerbations of chronic bronchitis, acute bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections and complicated intra-abdominal infections. In the US, Avelox is marketed by Bayer's partner Schering-Plough Corp. maria.sheahan@thomson.com mas/wj/mas/wj COPYRIGHT Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.